beeldscherm schreef op 1 september 2014 10:23:
Het is een oud gezegde dat eindigt op, and be back in September,maar te hopen dat dit ook voor Mdxhealth zo is,evenzo komt er de laatste tijd behoorlijk wat interesse uit China voor de Pharma ind.,zie Ablynx,
China: a dangerous game that pharma must play
www.pharmafile.com/news/193561/china-...hierin worden toch de Roche v/d wereld genoemd,
...
One means of tackling this is via private insurance for specific diseases, such as that operated by Swiss cancer drug specialist Roche, together with insurance firm SwissRe.
“This has reached very large numbers of people in just 18 months, and has also created a market for modern cancer drugs,” he says.
Eric Althoff, the head of global media relations at Novartis, adds that all populations of developing countries which continue to rapidly grow in both size and age are facing unprecedented health challenges.
“This is particularly apparent in China, where 85% of deaths are caused by chronic, non-communicable diseases, such as cancer and heart disease, compared to 63% worldwide,” Althoff says.
China sees 3.12 million new cancer cases each year and, according to the National Central Cancer Registry under the Ministry of Health, there has been an 18.74% incidence rate of lung cancer.
Additionally, China has the largest diabetic population in the world: 90 million Chinese currently suffer from diabetes and by 2030, 40 million more citizens will have the disease.
“To meet these rising numbers, Novartis and other healthcare companies are investing heavily in research, prevention, diagnosis and treatment of these conditions,” Althoff says.
het aandeel Mdxhealth zou natuurlijk vleugels krijgen mocht er nieuws uit China komen...